| 0 (0%) | 12-26 20:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.75 | 1-year : | 0.88 |
| Resists | First : | 0.65 | Second : | 0.75 |
| Pivot price | 0.61  |
|||
| Supports | First : | 0.47 | Second : | 0.39 |
| MAs | MA(5) : | 0.57  |
MA(20) : | 0.61 |
| MA(100) : | 0.57 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.4 |
D(3) : | 15.7 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 2.3 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PSTV ] has closed above bottom band by 26.9%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.58 |
| Low: | 0.55 - 0.55 | 0.55 - 0.55 |
| Close: | 0.57 - 0.57 | 0.57 - 0.57 |
Fri, 26 Dec 2025
Aug Final Week: Why CCEP stock is rated strong buy - Layoff News & Expert-Curated Trade Recommendations - moha.gov.vn
Sun, 21 Dec 2025
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Thu, 11 Dec 2025
New Analyst Forecast: $PSTV Given $5 Price Target - Quiver Quantitative
Thu, 11 Dec 2025
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Thu, 20 Nov 2025
Plus Therapeutics (NASDAQ: PSTV) Humana agreement lifts CNSide assay coverage to 67M - Stock Titan
Thu, 13 Nov 2025
$PSTV stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 137 (M) |
| Shares Float | 137 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 7,400 (K) |
| Shares Short P.Month | 7,870 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | 0 % |
| Operating Margin | -320.9 % |
| Return on Assets (ttm) | -65.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -4.1 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.6 |
| PEG Ratio | 0 |
| Price to Book value | 14.26 |
| Price to Sales | 14.9 |
| Price to Cash Flow | -4.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|